Shanghai RAAS Blood Products Co., Ltd.

Company Profile

Since its establishment, the Company has always focused on the blood products industry. Through years of efforts in the industry, the Company has, by adhering to product quality, persevering in technological innovation, keenly observing clinical needs, and deeply exploring industrial value, gradually built a unique competitive advantage in the industry. 1. Leading the industry in terms of scale and strength, and setting a benchmark for brand value The overall scale of the company takes the leading position in China’s blood products industry. As a leading Chinese producer of blood products with rational structure, diverse products and high plasma utilization rate, the Company now has 6 production bases for blood products in Shanghai, Zhengzhou, Hefei, Wenzhou, Nanning and Hengyang, and 55 single-collecting plasma stations, which are located in 11 provinces (autonomous regions), namely,Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi and Shandong, with the number of plasma stations, the regions and the collection area. (Autonomous Region). The number of plasma collection stations, their geographical distribution, and plasma collection volume rank among the top in the industry; its products are in three categories, namely, albumin, immunoglobulin and coagulation factors. At present, it is one of the few Chinese producers of blood products that can extract six components from plasma. It is also one of the Chinese producers that produce the most diverse coagulation factors. Always adhering to the quality policy of "safety, quality, and efficiency", the Company practices the brand commitment of "Shanghai RAAS as Health Guard", and is committed to making more and better drugs, creating new drugs, and benefiting society. 2. Leading Quality: The quality management system covering the entire value chain ensures the excellent operation The Company has established a comprehensive quality management system that covers the entire value chain, including quality management for plasma stations, design and development of products, management on suppliers, management on facilities and equipment, management on production process, quality control, quality assurance, and post-market quality management, so as to ensure that every link meets excellent standards. Benchmarking international drug quality management standards and codes, the Company has continuously promoted the construction of digital and information systems throughout the entire process from raw plasma collection to terminal clinical use, so as to continuously improve the Company's product quality assurance level, and ensure brand competitiveness in the market. Through digital transformation, the Company has achieved the real-time monitoring and precise management of product quality, further enhancing the safety and effectiveness of its products. In addition, in light of the characteristics of pharmaceutical enterprises, the Company has introduced the concept, methods, and tools of lean production, continuously promoted the activities such as on-site 5S management and lean improvement, and explored a new paradigm of "Lean GMP" management in the blood products industry. By continuously improving and optimizing the production process, the production efficiency has been effectively improved, the costs have been reduced, and the stability and consistency of product quality have been ensured. 3. Leading Innovation: Breaking through bottlenecks with a multidimensional R&D system, the Company has entered the new track of innovative pharmaceutical technology Since its establishment, the Company has focused on research and innovation, and has been deeply involved in the field of biomedicine. By building a multidimensional R&D system involving "independent innovation + patent introduction + technology cooperation", the Company has achieved a series of breakthroughs in key therapeutic fields, creating multiple domestic "firsts" including the first virus killing human coagulation factor product, and has obtained multiple intellectual property rights such as invention patents, one of which has been granted in eight countries including China and the United States. Focusing on the forefront of hemophilia treatment, the Company has selected unique and innovative targets for the development of recombinant protein drugs. The innovative research result in the field of procoagulant non-factor therapy for hemophilia ("SR604" injection) has entered the phase-IIb clinical trial research stage, and the clinical trial application for the indication of "prevention and treatment of bleeding episodes in hemophilia patients" has been accepted by the National Medical Products Administration. The Company is simultaneously promoting the layout of multiple R&D pipelines. Relying on platform technology advantages, the existing varieties have demonstrated excellent potential for the expansion of proprietary drugs and new indications, laying a solid foundation for the continuous development of innovative drugs. 4. Leading Strategy: Through the value fission and strategic leap under industrial integration, the Company has forged its core capabilities in M&A integration As a pioneer in the integration of the blood products industry, the Company has rich experience in M&A, and has formed three core advantages: Firstly, it has established a full-cycle management loop of "strategic M&A - fine integration - value reshaping", further enhancing its profitability and comprehensive competitiveness; secondly, relying on the dual-wheel synergy effect of industrial operation and capital operation, the Company has achieved synchronous leaps in economies of scale and creation of value, with high integration efficiency of M&A targets; thirdly, developing a unique M&A methodology of "value discovery + management empowerment + ecological amplification of value", the Company, guided by a forward-looking industrial chain value map, has built a full-cycle value engine of "strategic insight - element activation - ecological reconstruction" through technological integration & innovation, channel sharing, and management output. In June 2025, the Company successfully completed the acquisition of Nanyue Biopharming, further enhancing the overall scale of the company and the coverage of plasma stations. The continuous strengthening of these M&A advantages drives the Company to accelerate its goal of becoming a world-class biopharmaceutical enterprise. 5. Leading Overseas Layout: Intensifying its efforts in overseas layout, the Company has gradually globalized its blood products business Against the backdrop of intensified global competition in the biopharmaceutical industry, the Company has built a solid foundation for development with strong R&D capabilities, and accelerated the overseas market expansion with the support from strategic partners. With Haier Group becoming the actual controller of the Company and the Company reaching a deep strategic cooperation with its shareholder, namely the global blood products giant Grifols, the Company has comprehensively upgraded its overseas development layout, achieving multidimensional breakthroughs from resource integration, and market expansion to operational optimization, and gradually building a "domestically leading and globally coordinated" business pattern, so as to inject strong impetus into the global development of the blood products business. The Company will continue to adhere to the development strategy of "expanding plasma" and "de-plasma" step by step, and make all efforts to become a world-class biopharmaceutical enterprise, so as to make contribution to the common realization of the vision of "lifelong health for all people" and "Healthy China".